Stapokibart for children with atopic dermatitis
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medicine called Stapokibart for children aged 2 to 11 with moderate-to-severe atopic dermatitis (also called eczema) that hasn't improved with topical creams. The medicine is given as an injection and may help reduce itching and skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 11 years old.
- Your child must have a confirmed diagnosis of atopic dermatitis (eczema).
- The eczema must be moderate to severe and not well controlled with topical medications (like creams or ointments).
- Your child cannot have used certain other biologic medicines (like dupilumab) recently.
- Your child cannot have used immunosuppressants, UV therapy, or certain topical treatments in the weeks before starting.
- Your child cannot have had acute flare-ups of eczema in the last 4 weeks or have certain eye problems related to eczema.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a follow-up for children who have already completed the first 18 weeks of treatment with the study medicine for atopic dermatitis (also called eczema). It tests whether the medicine continues to be safe and effective over a longer time.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This study tests the long-term safety and effectiveness of a medicine called Afimkibart for people with atopic dermatitis (eczema). It is for people who already completed a previous study of this medicine and had at least a 50% improvement in their eczema.
This study tests a new injected medication called XKH001 for people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't improved with standard creams. The goal is to see if it can reduce the severity of eczema and itching.
This study tests an injection called ADSTEM for people with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams or other treatments. The goal is to see if it can help reduce symptoms like itching and rash.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.